HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1,25-dihydroxyvitamin D3-3-bromoacetate

structure given in first source

Also Known As:

1,25(OH)2-BE; 14C-1,25(OH)2D3-3-BE; 1alpha,25-dihydroxyvitamin D3-3beta-bromoacetate; AMPI-109

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ray, Rahul: 3 articles (10/2016 - 06/2010)
2.	DeGala, Gregory D: 2 articles (10/2016 - 03/2016)
3.	Gari, Hamid H: 2 articles (10/2016 - 03/2016)
4.	Lambert, James R: 2 articles (10/2016 - 03/2016)
5.	Lucia, M Scott: 2 articles (10/2016 - 03/2016)
6.	Edgerton, Susan M: 1 article (03/2016)
7.	Fan, Zeying: 1 article (03/2016)
8.	Fosmire, Susan: 1 article (03/2016)
9.	Gearheart, Christy M: 1 article (03/2016)
10.	Porter, Christopher C: 1 article (03/2016)

Related Diseases

1.	Disease Progression 03/29/2016 - "Collectively, our study is proof-of-concept that AMPI-109, a selectively active agent against TNBC cell lines, can be used as a molecular tool to uncover unique drivers of disease progression, such as PRL-3, which we show promotes oncogenic phenotypes in TNBC cells. "
2.	Triple Negative Breast Neoplasms 03/29/2016 - "Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers."
3.	Pancreatic Neoplasms (Pancreatic Cancer) 06/01/2010 - "Anti-growth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cells."
4.	Neoplasm Metastasis (Metastasis) 10/01/2016 - "We previously reported that the TNBC-specific inhibitor, AMPI-109, significantly impairs the ability of TNBC cells to migrate and invade by reducing levels of the metastasis-promoting phosphatase, PRL-3. "

Related Drugs and Biologics

1.	Phosphoric Monoester Hydrolases (Phosphatases)
2.	Antineoplastic Agents (Antineoplastics)